Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

Amgen has collaborated with Micromet on its BiTE novel oncology platform since last July and it obviously has liked what it has seen, and then in December it heard news of promising Phase II data with a Micromet molecule for acute lymphocytic leukaemia (ALL), a difficult to treat blood cancer. This has now culminated in Amgen’s announcement that it will acquire Micromet for $11 per share in cash, for a total of around $1.16 billion, a 33% premium over the company’s closing price of $8.28 just before the deal was announced.

Amgen has collaborated with Micromet on its BiTE novel oncology platform since last July and it obviously has liked what it has seen, and then in December it heard news of promising Phase II data with a Micromet molecule for acute lymphocytic leukaemia (ALL), a difficult to treat blood cancer. This has now culminated in Amgen’s announcement that it will acquire Micromet for $11 per share in cash, for a total of around $1.16 billion, a 33% premium over the company’s closing price of $8.28 just before the deal was announced.

The appeal is this new class of antibodies, called bi-specific T cell engager (BiTE) antibodies, which pack a unique punch...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By 

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

More from Therapeutic Category

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.